IBN SINA Pharmaceutical Industry Past Earnings Performance
Past criteria checks 2/6
IBN SINA Pharmaceutical Industry has been growing earnings at an average annual rate of 12.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 13.8% per year. IBN SINA Pharmaceutical Industry's return on equity is 16.4%, and it has net margins of 5.3%.
Key information
12.5%
Earnings growth rate
12.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.0% |
| Revenue growth rate | 13.8% |
| Return on equity | 16.4% |
| Net Margin | 5.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How IBN SINA Pharmaceutical Industry makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 11,231 | 592 | 3,611 | 0 |
| 30 Jun 24 | 11,371 | 671 | 3,617 | 0 |
| 31 Mar 24 | 10,866 | 690 | 3,498 | 0 |
| 31 Dec 23 | 10,335 | 648 | 3,403 | 0 |
| 30 Sep 23 | 9,566 | 624 | 3,200 | 0 |
| 30 Jun 23 | 9,125 | 605 | 3,051 | 0 |
| 31 Mar 23 | 8,712 | 614 | 2,879 | 0 |
| 31 Dec 22 | 8,568 | 607 | 2,827 | 0 |
| 30 Sep 22 | 8,570 | 609 | 2,787 | 0 |
| 30 Jun 22 | 8,480 | 606 | 2,745 | 0 |
| 31 Mar 22 | 8,384 | 562 | 2,694 | 0 |
| 31 Dec 21 | 8,296 | 563 | 2,653 | 0 |
| 30 Sep 21 | 8,015 | 529 | 2,569 | 0 |
| 30 Jun 21 | 7,376 | 489 | 2,368 | 0 |
| 31 Mar 21 | 6,986 | 433 | 2,256 | 0 |
| 31 Dec 20 | 6,730 | 419 | 2,165 | 0 |
| 30 Sep 20 | 6,384 | 405 | 2,054 | 0 |
| 30 Jun 20 | 6,192 | 393 | 1,997 | 0 |
| 31 Mar 20 | 6,051 | 389 | 1,921 | 0 |
| 31 Dec 19 | 5,761 | 378 | 1,824 | 0 |
| 30 Sep 19 | 5,473 | 350 | 1,739 | 0 |
| 30 Jun 19 | 5,264 | 336 | 1,673 | 0 |
| 31 Mar 19 | 4,978 | 483 | 1,590 | 0 |
| 31 Dec 18 | 4,759 | 469 | 1,514 | 0 |
| 30 Sep 18 | 4,747 | 467 | 1,517 | 0 |
| 30 Jun 18 | 4,657 | 452 | 1,487 | 0 |
| 31 Mar 18 | 4,543 | 267 | 1,448 | 0 |
| 31 Dec 17 | 4,500 | 258 | 1,433 | 0 |
| 30 Sep 17 | 4,312 | 252 | 1,376 | 0 |
| 30 Jun 17 | 4,009 | 234 | 1,282 | 0 |
| 31 Mar 17 | 3,951 | 224 | 1,265 | 0 |
| 31 Dec 16 | 3,781 | 224 | 1,213 | 0 |
| 30 Sep 16 | 3,689 | 221 | 1,186 | 0 |
| 30 Jun 16 | 3,491 | 203 | 1,120 | 0 |
| 31 Mar 16 | 3,294 | 193 | 1,051 | 0 |
| 31 Dec 15 | 3,163 | 178 | 1,046 | 0 |
| 30 Sep 15 | 2,931 | 147 | 979 | 0 |
| 30 Jun 15 | 2,922 | 145 | 985 | 0 |
| 31 Mar 15 | 2,815 | 136 | 962 | 0 |
| 31 Dec 14 | 2,679 | 127 | 888 | 0 |
| 30 Sep 14 | 2,609 | 102 | 882 | 0 |
| 30 Jun 14 | 2,454 | 99 | 827 | 0 |
| 31 Mar 14 | 2,305 | 90 | 783 | 0 |
| 31 Dec 13 | 2,209 | 87 | 744 | 0 |
Quality Earnings: IBNSINA has high quality earnings.
Growing Profit Margin: IBNSINA's current net profit margins (5.3%) are lower than last year (6.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IBNSINA's earnings have grown by 12.5% per year over the past 5 years.
Accelerating Growth: IBNSINA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: IBNSINA had negative earnings growth (-5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.2%).
Return on Equity
High ROE: IBNSINA's Return on Equity (16.4%) is considered low.